Endeavor Health and GoPath Diagnostics introduce a new genetic screening tool for aggressive prostate cancer, aiming to improve clinical outcomes through early detection.
Endeavor Health researchers have co-developed a novel genetic test for aggressive prostate cancer, marking a significant advancement in their clinical diagnostic capabilities. The clinical validation of this test, supported by studies published in peer-reviewed journals like 'Prostate Cancer and Prostatic Disease', positions the organization as a leader in precision oncology.
It is the first genetic test of its kind to be made clinically available for identifying aggressive prostate cancer.
GoPath Diagnostics is set to benefit from the commercialization of this novel genetic test, which provides a unique market differentiator in the oncology diagnostic space. By partnering with Endeavor Health, the company leverages clinical research to drive revenue through the deployment of this specialized diagnostic tool.
The test's efficacy is supported by research findings published in 'Prostate Cancer and Prostatic Disease' and 'The Prostate' journals.
Endeavor Health and GoPath Diagnostics have unveiled a first-of-its-kind genetic test designed to identify aggressive prostate cancer. The clinical validation, published in leading medical journals, marks a significant advancement in diagnostic precision for oncology patients.
It is the first clinically available genetic test specifically designed to identify aggressive forms of prostate cancer, providing a new tool for clinicians.